/
RSS Feed
SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-based chemotherapy, according to breast medical oncologist and assistant professor of internal medicine, Nan Chen MD, from the University of Chicago.
She reported her group’s latest analysis of records from 2,528 patients in the TAILORx trial at the 2024 San Antonio Breast Cancer Symposium comparing patients being treated after surgery with taxane/cyclophosphamide chemotherapy with or without additional anthracycline. After her talk she discussed the findings with Peter Goodwin:
